Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a green tea compound prevent second heart attacks?

NCT ID NCT06590012

Disease control Sponsor: Institute for Atherosclerosis Research, Russia Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 15, 2026 · Last updated Jul 21, 2026 · Updated 3 times

Summary

This trial tests whether a dietary supplement called Tertinat, containing epigallocatechin-3-gallate, can reduce major heart problems in people with atherosclerosis who have recently had bypass or stent surgery. Over two years, participants take either the supplement or a placebo alongside standard care. The study measures heart attacks, strokes, unstable angina, heart failure, and the need for repeat procedures.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a dietary supplement called Tertinat, which contains epigallocatechin-3-gallate
What this could lead to
If it works, this could point toward a simple dietary supplement that lowers the risk of heart attacks, strokes, and repeat surgeries in people with hardened arteries.
What could go wrong
This is a Phase 2 trial, so it is still early. The supplement may not reduce heart events as hoped, and results may not apply to everyone with atherosclerosis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

1,228 people

The number who actually took part.

Started

Aug 2024

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

45 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Men and women aged 45-75 * Patients with atherosclerotic cardiovascular diseases who have passed revascularization procedure within last 3 months prior to the inclusion in the study * Atherosclerotic cardiovascular diseases may include coronary heart disease, and/or coronary atherosclerosis, and/or atherosclerosis of brachiocephalic / limb / renal arteries. * Patients who have undergone instrumental and laboratory examinations (ECG, ultrasound / CT / angiography, biochemical tests - total cholesterol, triglycerides, LDL cholesterol, HDL cholesterol, blood glucose, C-reactive protein), and the data from above examinations from medical records are available. * The principal patient's abitity for follow-up questioning and examination at 12 and 24 months apart from inclusion in the study. * The signed informed consent. Exclusion Criteria: * Critical and urgent cardiovascular conditions: tissue ischemia stage III-IV, stroke, acute coronary syndrome, acute myocardial infarction, chronic heart failure III and IV class NYHA (New York Heart Association). * Other critical and urgent conditions not associated with cardiovascular diseases, including the need for urgent interventions, chronic renal failure stages IV-V (creatinine clearance \< 30 ml / min according to the Cockcroft-Gault Equation) * Systemic autoimmune diseases in medical history, including: rheumatoid arthritis, systemic lupus erythematosus, autoimmune thyroiditis, autoimmune vasculitis, ulcerative colitis. * Significant weight loss (\> 10% of body weight in the previous year) of unknown etiology. * Conditions that limit adherence to participation in the study (dementia, neuropsychiatric diseases, drug addiction, alcoholism, etc.). * Participation in other clinical studies (or use of investigational substances) within 3 months prior to study entry. * Carriers of HIV or viral hepatitis * Pregnancy or breast feeding * Refusal to participate in the study / to sigh informed concent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atheroscleroses, coronary are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atherosclerosis carotid artery disorder carotid stenosis coronary artery disorder coronary atherosclerosis peripheral arterial disease renal artery atheroma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atheroscleroses, coronary Atherosclerosis Carotid atherosclerosis

Contacts and locations

Locations

  • A. V. Vishnevsky National Medical Research Center of Surgery (Federal State Budgetary Institution)

    Moscow, 117997, Russia

  • Cardiology Research Institute - Branch of the Federal State Budgetary Scientific Institution "Tomsk National Research Medical Center of the Russian Academy of Sciences"

    Tomsk, 634012, Russia

  • City Polyclinic No. 109 (State Budgetary Healthcare Institution)

    Saint Petersburg, 192283, Russia

  • LLC "RC Medical"

    Novosibirsk, 630005, Russia

  • Lipetsk Regional Clinical Hospital

    Lipetsk, 398055, Russia

  • Llc "Sfera-Med"

    Saint Petersburg, 197342, Russia

  • M. F. Vladimirsky Moscow Regional Research Clinical Institute

    Moscow, 129110, Russia

  • N. N. Burdenko Voronezh State Medical University

    Voronezh, 394036, Russia

  • Research Institute for Complex Issues of Cardiovascular Diseases

    Kemerovo, 650000, Russia

  • State Autonomous Healthcare Institution "Interregional Clinical Diagnostic Center"

    Kazan', 420101, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.